Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Plus EGFR-TKIs in Advanced NSCLC
NCT07669051Phase 2Active, not recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Started Jan 2026; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07669051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07669051.